^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Hansoh Xinfu (flumatinib) (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CHEMO-FREE TREATMENT OF VAF INDUCE A EARLY AND DEEP MOLECULAR RESPONSEIN IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA : A PROSPECTIVE, SINGLE ARM, PHASE II STUDY
Published date:
05/11/2023
Excerpt:
We evaluated the efficacy and safety of a chemo-free combination of venetoclax, azacitidine and flumatinib (VAF) in patients with ND Ph+AL and accelerated or blast phase chronic myeloid leukemia(CML)....After one cycle of VAF, CR/CRi rate was 100% (13/13). Of the 13 patients, 92.3% had a molecular response with76.9% CMR and 15.4% MMR, and another one achieved a CCyR. The CMR rate at end of two cycles of VAF, the primary endpoint, increased to 83.3%....VAF is a highly effective and safe strategy to achieve early and deep molecular response in patients with ND Ph+AL in the frontline setting, providing a potential Day ward/Out-patient treatment strategy for Ph+AL.
Secondary therapy:
azacitidine
